SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?

Inhibitors of sodium-glucose cotransporters type-2 are the most recent addition to the armamentarium of oral anti-diabetic agents. This class of drugs has shown promising results in glycemic control and most importantly to reduce cardiovascular disease (CVD) mortality risk. Despite the encouraging data, there is concern regarding their potential for causing or worsening peripheral artery disease (PAD), which may increase the risk of lower extremity amputations. Following the publication of results of CANVAS and CANVAS-R trials which revealed that leg and mid-foot amputations occurred about twice as often in patients treated with canagliflozin compared to placebo, the Food and Drug Administration (FDA) in the United States issued a black box warning of leg and foot amputations associated with canagliflozin use.

Source: Current Problems in Cardiology - July 6, 2018 Category: Cardiology Authors: Subhankar Chatterjee, Dhrubajyoti Bandyopadhyay, Raktim K Ghosh, Uddalak Majumdar, Ashish Aneja, Carl J. Lavie, Prakash Deedwania Source Type: research